Skip to content
AnalystLens

NBIX · Neurocrine Biosciences

31 filings

10-K

NBIX 10-K Annual Reports

Neurocrine Biosciences - 31 annual reports

Filing record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Sep ’19Sep ’19
  3. Material agreement8-K · Nov ’21Nov ’21
  4. Leadership change8-K · Nov ’25Nov ’25
  1. 2025

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2025

    Neurocrine Biosciences, Inc. reported total revenues of $2.86 billion for 2025, up from $2.36 billion in 2024, driven by net product sales of $2.83 billion. INGREZZA net product sales were $2.51 billion for 2025 versus $2.31 billion in 2024, and CRENESSITY, launched in December 2024, generated $301.2 million in its first full year. The company's net income rose to $478.6 million, or $4.67 per diluted share, from $341.3 million, or $3.29 per diluted share, in 2024. Operating income was $619.1 million, compared with $570.5 million a year earlier, while research and development spending increased to $1.02 billion from $731.1 million, reflecting Phase 3 programs for osavampator in major depressive disorder and direclidine in schizophrenia. The company ended 2025 with $2.54 billion in cash, cash equivalents and marketable securities, up from $1.82 billion, and generated $782.7 million in operating cash flow. It repurchased $167.7 million of stock during 2025 and had $332.3 million remaining under its 2025 repurchase program. Its sales force expansion for INGREZZA and CRENESSITY is expected to be completed by the end of the first quarter of 2026. Key risks disclosed include a civil investigative demand from the U.S. Department of Justice in August 2025 concerning INGREZZA sales and marketing, a Paragraph IV patent challenge from Zydus relating to INGREZZA SPRINKLE, customer concentration in which four customers represent over 90% of gross product sales, and Medicare drug pricing pressures under the Inflation Reduction Act. The company also disclosed that two Phase 3 valbenazine studies and a Phase 2 MDD study did not meet their primary endpoints in 2025.

    Feb 11, 2026
  2. 2024

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2024

    Neurocrine Biosciences, Inc. reported net product sales of $2.33 billion for 2024, up from $1.86 billion in 2023, driven primarily by INGREZZA, which generated $2.31 billion in net product sales and accounted for substantially all product sales. Total revenues were $2.36 billion, operating income was $570.5 million, and net income was $341.3 million, compared with $249.7 million in 2023. Diluted EPS was $3.29. Results were partly offset by $138.4 million of charges associated with the conversion and settlement of the 2024 convertible senior notes and by higher research and development expense of $731.1 million, up from $565.0 million. The company launched CRENESSITY for classic congenital adrenal hyperplasia in December 2024 following FDA approval, and it expanded its pipeline. Osavampator advanced into Phase 3 for major depressive disorder after the company converted its Takeda profit-share arrangement into a royalty-bearing license in January 2025. NBI-1117568 completed Phase 2 in schizophrenia and is expected to enter Phase 3 in the first half of 2025. Cash, cash equivalents and marketable securities totaled $1.82 billion at year-end, and working capital was $1.22 billion. Investors should note the concentration of revenue: four customers represented approximately 93% of total product sales in 2024. The filing also highlights exposure to Medicare drug price negotiation under the Inflation Reduction Act, although INGREZZA qualified for the small biotech exception and the specified small manufacturer discount phase-in. The company completed a $300.0 million accelerated share repurchase in February 2025, and its CEO transitioned from Kevin Gorman to Kyle Gano in October 2024.

    Feb 10, 2025
  3. 2023

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2023

    Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported total revenues of $1,887.1 million for 2023, up from $1,488.7 million in 2022, driven by net product sales of $1,860.6 million. INGREZZA net product sales totaled $1.8 billion in 2023 (about 99% of total net product sales), reflecting higher prescription demand, continued direct-to-consumer advertising and the expansion of the sales force completed in April 2022. Net income rose to $249.7 million ($2.47 diluted EPS) from $154.5 million in 2022, while operating income was $250.9 million. Operating expenses increased, with research and development at $565.0 million and SG&A at $887.6 million, and acquired in-process R&D of $143.9 million tied to the Voyager collaboration. The balance sheet strengthened, with cash, cash equivalents and marketable securities of $1,719.1 million at December 31, 2023, versus $1,288.7 million a year earlier. Operating cash flow was $389.9 million. The company's convertible senior notes due May 2024 had $170.4 million principal outstanding, and the company elected to settle conversions in cash. The accumulated deficit narrowed to $157.1 million. The company also reported Phase 3 positive top-line data for crinecerfont in adult and pediatric congenital adrenal hyperplasia, with NDA submissions expected in the second quarter of 2024, and settled all patent litigation over INGREZZA generics, with generic entry permitted beginning March 1, 2038, or earlier under certain circumstances. Key risks in the filing include reliance on a limited number of customers (four customers represented approximately 91% of 2023 product sales), dependence on federal healthcare program payors including Medicare and Medicaid, the Inflation Reduction Act's drug price negotiation provisions, reliance on third-party contract manufacturers, and the cost of pipeline programs that did not meet primary endpoints in the fourth quarter of 2023.

    Feb 9, 2024
  4. 2022

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2022

    Neurocrine Biosciences, Inc. reported 2022 total revenues of $1,488.7 million, up from $1,133.5 million in 2021, and net income of $154.5 million, compared with $89.6 million in 2021. Product sales are driven almost entirely by INGREZZA, which had net product sales of $1,427.8 million in 2022, an increase of $345.9 million, or 32.0%, attributed to increased new patient starts, higher prescriptions, and continued investment in a direct-to-consumer advertising campaign and an expanded sales force. Operating income was $249.0 million, but research and development expense rose to $463.8 million from $328.1 million and selling, general and administrative expense rose to $752.7 million from $583.3 million. Diluted earnings per share were $1.56, compared with $0.92 in 2021. The balance sheet strengthened in liquidity while debt was reduced. Cash, cash equivalents and marketable securities totaled $1,288.7 million at December 31, 2022. The company repurchased $210.8 million of its 2.25% convertible senior notes due 2024 for $279.0 million in cash, recognizing a $70.0 million loss on extinguishment, leaving $170.4 million outstanding. Management states that existing capital resources and anticipated revenues are sufficient to meet funding requirements for at least the next 12 months. The company also reported an accumulated deficit of $406.8 million and operating cash flow of $339.4 million for 2022. The filing highlights concentration and legal risk. Four customers represented approximately 89% of total product revenue for 2022 and approximately 95% of accounts receivable at December 31, 2022. Several generic applicants have filed ANDAs against INGREZZA, and the company's patent suits are consolidated in the District of Delaware with trial scheduled for January 2, 2024. Pipeline catalysts include an FDA target action date of August 20, 2023 for valbenazine in chorea associated with Huntington disease, and top-line data expected in the second half of 2023 for crinecerfont in congenital adrenal hyperplasia.

    Feb 9, 2023
  5. 2021

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2021

    Neurocrine Biosciences, Inc. reported 2021 total revenues of $1.13 billion (up from $1.05 billion in 2020), driven by net product sales of $1.09 billion. INGREZZA net product sales were $1.1 billion for 2021 ($1,081.9 million), up $88.8 million, or 8.9%, from 2020, primarily due to increased total prescriptions. ONGENTYS net product sales were $8.2 million in its first full year after its September 2020 launch. The company was profitable in 2021, with net income of $89.6 million, or $0.92 diluted EPS, compared with $407.3 million in 2020, which included a $296.3 million benefit from releasing most of its deferred tax valuation allowance. Operating income was $102.5 million, versus $163.0 million in 2020, as SG&A rose to $583.3 million from $433.3 million on commercial investment, including the May 2021 launch of the 'TD Spotlight' direct-to-consumer campaign. The company ended 2021 with $1,272.0 million in cash, cash equivalents and marketable securities, and cash provided by operating activities was $256.5 million. Convertible senior notes due 2024 had $381.2 million principal outstanding, and the company stated its existing resources are sufficient for at least the next twelve months. Two customers accounted for approximately 82% of total product revenue in 2021. Subsequent to year end, on February 8, 2022, the company entered into a lease for a four-building San Diego campus of up to approximately 535,000 gross square feet to serve as its new headquarters. Pipeline milestones include positive top-line KINECT-HD Phase III data for valbenazine in Huntington chorea, with an sNDA planned for the second half of 2022, and a $100.0 million upfront payment to Heptares that was expensed as IPR&D. Generic challengers filed ANDAs against INGREZZA in 2021, and the company sued them in July 2021. Management expects R&D expense and commercial investment to keep rising, and the filing notes material exposure to generic entry and payor pricing pressure.

    Feb 11, 2022
  6. 2020

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2020

    Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, reported full-year 2020 results in this Form 10-K filed February 5, 2021. Total revenues were $1,045.9 million for 2020, up from $788.1 million in 2019, driven by INGREZZA net product sales of $993.1 million. Net product sales were $994.1 million, including the first ONGENTYS sales after its September 2020 U.S. launch. The company reported net income of $407.3 million, or $4.16 per diluted share, compared with $37.0 million in 2019. That result includes a non-cash income tax benefit of $300.6 million, which reflects a $296.3 million release of the valuation allowance against deferred tax assets. The filing states that beginning in 2021 the company expects to record income tax expense at an estimated rate approximating statutory rates, which would significantly reduce net income. Operating income was $163.0 million, compared with $72.3 million in 2019, after $164.5 million of acquired in-process R&D tied to the Idorsia and Takeda collaborations. Research and development expense rose to $275.0 million and SG&A to $433.3 million. Cash, cash equivalents and debt securities available-for-sale totaled $1.0 billion at year-end, and net cash from operating activities was $228.5 million. In November 2020 the company repurchased $136.2 million of its 2.25% convertible senior notes due 2024 for $186.9 million in cash, leaving $381.3 million outstanding and an $18.4 million loss on extinguishment. The pipeline includes a Phase III CAHtalyst study of crinecerfont in adult classic CAH, a Phase III KINECT-HD study of valbenazine in Huntington's disease with top-line data expected in Q4 2021, and a Phase II study of the DAAO inhibitor NBI-1065844 in negative symptoms of schizophrenia with top-line data expected in Q1 2021. The company also notified Voyager of the termination of the NBIb-1817 Parkinson's program, effective August 2, 2021, after the FDA placed a clinical hold on the RESTORE-1 study. The filing notes that the company's two largest customers represented approximately 86% of product revenues in 2020.

    Feb 5, 2021
  7. 2019

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2019

    Neurocrine Biosciences, Inc. (filed under this name; ticker NBIX) reported its Form 10-K for fiscal 2019. The company describes itself as a commercial-stage biopharmaceutical company focused on neurological, endocrine and psychiatric disorders. Its primary commercial product is INGREZZA (valbenazine) for tardive dyskinesia, approved by the FDA in April 2017. Net product sales of INGREZZA were $752.9 million in 2019, up from $409.6 million in 2018 and $116.6 million in 2017. Total revenues were $788.1 million, and the company reported net income of $37.0 million, or $0.39 per diluted share, compared with $21.1 million in 2018 and a net loss of $142.5 million in 2017. The filing highlights several pipeline catalysts. The FDA accepted an NDA for opicapone in Parkinson's disease with a PDUFA target action date of April 26, 2020, and AbbVie's NDA for elagolix in uterine fibroids with a PDUFA date in the second quarter of 2020. Crinecerfont for congenital adrenal hyperplasia is planned for a global registration study in mid-2020. Operating expenses increased, including $154.3 million of acquired in-process R&D tied to the Voyager and Xenon collaborations, and SG&A rose to $354.1 million. The company held $970.2 million in cash, cash equivalents and marketable securities at December 31, 2019, and reported $152.1 million of operating cash flow for 2019. Key risks disclosed include concentration of revenue, with two customers accounting for approximately 86% of gross product sales in 2019, and the conditional conversion feature of the $517.5 million 2.25% convertible senior notes due 2024, which was triggered at December 31, 2019, allowing conversion from January 2, 2020 through March 31, 2020. The notes are classified as a current liability. The company also reported an accumulated deficit of $1.1 billion and continued exposure to healthcare reform and drug pricing scrutiny.

    Feb 7, 2020
  8. 2018

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2018

    Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported 2018 total revenues of $451.2 million, up from $161.6 million in 2017, driven primarily by INGREZZA net product sales of $409.6 million (versus $116.6 million in 2017). The company reported net income of $21.1 million, or $0.22 per diluted share, compared with a net loss of $142.5 million in 2017. Collaboration revenue was $41.6 million in 2018, including a $40 million event-based milestone from AbbVie upon FDA approval of ORILISSA for endometriosis pain. Total operating expenses rose to $414.3 million, with SG&A of $248.9 million and R&D of $160.5 million, reflecting the INGREZZA commercial launch and pipeline progression. Cash, cash equivalents and investments totaled $866.9 million at year-end, against $517.5 million of 2.25% convertible senior notes due 2024. The company states that existing resources are sufficient for at least the next 12 months. The filing highlights concentration and execution risks: three customers accounted for approximately 93% of product revenue in 2018, INGREZZA relies on single-source suppliers, and the company has an accumulated deficit of approximately $1.2 billion. Management also disclosed that T-Force GOLD, a Phase IIb study of valbenazine in pediatric Tourette syndrome, failed to meet its primary endpoint in December 2018. Subsequent to year-end, on January 28, 2019, the company agreed to a collaboration with Voyager Therapeutics involving a $115 million upfront cash payment and a $50 million equity purchase, with Voyager eligible for up to $1.7 billion in milestones across four gene therapy programs. Pipeline near-term catalysts described in the filing include an anticipated NDA submission for elagolix in uterine fibroids in the middle of 2019 (partnered with AbbVie), an anticipated opicapone NDA submission in the second quarter of 2019, and initial NBI-74788 Phase II results in the first quarter of 2019.

    Feb 8, 2019
  9. 2017

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2017

    Neurocrine Biosciences, Inc. reported its first year of INGREZZA (valbenazine) commercial sales in its annual report for fiscal 2017. INGREZZA was approved by the FDA on April 11, 2017 for tardive dyskinesia (TD), and the commercial launch occurred on May 1, 2017 with a field-based sales team of approximately 160 personnel. Net product sales were $116.6 million for 2017, and total revenues were $161.6 million including $45.0 million in milestones and license fees. The company reported a net loss of $142.5 million, or $1.62 per share, compared with a net loss of $141.1 million in 2016. The company states it does not expect to be profitable for 2018, and expects revenue to increase, with higher operating expenses, general and administrative expenses and interest expense. The pipeline is led by elagolix, a GnRH antagonist partnered with AbbVie, for which AbbVie submitted an NDA for endometriosis in the third quarter of 2017 that was accepted for priority review with a PDUFA date in the second quarter of 2018. The company also lists INGREZZA for Tourette syndrome (Phase IIb, with top-line data expected in late 2018) and opicapone for Parkinson's disease, in-licensed from BIAL for a $30 million upfront fee. The T-Forward Tourette study did not meet its pre-specified primary endpoint. At December 31, 2017, cash, cash equivalents and investments totaled $763.3 million, against $517.5 million of 2.25% convertible senior notes due 2024 issued in May 2017. The company states its existing capital resources are sufficient to fund requirements for at least the next 12 months. The accumulated deficit was approximately $1.2 billion.

    Feb 13, 2018
  10. 2016

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2016

    Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is a neurological and endocrine-focused biopharmaceutical company with no approved products to date. As of December 31, 2016, it reported an accumulated deficit of approximately $1.1 billion, cash, cash equivalents and investments of $350.8 million, and a net loss of $141.1 million, or $1.63 per share, for 2016. Revenue was $15.0 million in 2016, all of it event-based revenue from AbbVie tied to the start of Phase III uterine fibroids development for elagolix. The company expects to be unprofitable in 2017. The company's near-term value rests on INGREZZA (valbenazine) for tardive dyskinesia, whose New Drug Application was submitted in August 2016 and accepted for priority review with a PDUFA target action date of April 11, 2017. Management plans to build a specialty sales force of approximately 140 professionals and expects general and administrative expenses to increase significantly in 2017 to support commercialization. Other programs include elagolix (partnered with AbbVie, with an endometriosis NDA targeted for Q3 2017), opicapone (licensed from BIAL in February 2017 for the US and Canada, with a $30 million upfront fee and up to $115 million in milestones), and early-stage Tourette syndrome, essential tremor and congenital adrenal hyperplasia programs. Key risks include the FDA decision on INGREZZA, reliance on single-source suppliers and collaborators, pending litigation from Mount Sinai over the AbbVie sublicense, and the need for additional funding. Management believes existing resources will be sufficient for at least the next 12 months.

    Feb 14, 2017
  11. 2015-A

    Neurocrine Biosciences Annual Report (Amendment), Year Ended Dec 31, 2015

    This Amendment No. 1 to Neurocrine Biosciences, Inc.'s Form 10-K for the fiscal year ended December 31, 2015 does not contain financial statements. It restates Part III, Items 10 through 14, and adds new Section 302 and 906 certifications under Item 15. The company says it filed this amendment because it did not expect its definitive proxy statement for the election of directors to be filed within 120 days after fiscal year-end, so the Part III information incorporated by reference from the proxy could not be relied on. The original Form 10-K was filed February 11, 2016. The filing describes Neurocrine's two lead late-stage programs: elagolix, a gonadotropin-releasing hormone antagonist for women's health partnered with AbbVie Inc., and valbenazine, a VMAT2 inhibitor for movement disorders that the company intends to commercialize in part. The compensation discussion states that the company met its 2015 corporate goals at the 100% level, citing positive Phase III tardive dyskinesia results, a successful Tourette syndrome Phase Ib study, an out-license of valbenazine in Japan and certain other Asian countries, and a public stock offering. It also states that the 2015 share price rose by approximately 250%. Ernst & Young LLP fees totaled $625,798 for 2015, compared with $598,293 for 2014. Ownership data as of March 15, 2016 show 86,571,700 common shares outstanding. The largest holders reported are FMR LLC at 14.9%, T. Rowe Price Associates at 11.1%, and BlackRock at 8.1%. All current executive officers and directors as a group hold 4.8%. Chief Executive Officer Kevin C. Gorman's 2015 total compensation was $5,011,967 in the Summary Compensation Table.

    Apr 29, 2016
  12. 2015

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2015

    Neurocrine Biosciences, Inc. (NBIX) reported a net loss of $88.9 million, or $1.05 per share, for 2015, compared with a net loss of $60.5 million in 2014. Revenue was $19.8 million, all recognized from the up-front license fee under the March 2015 Mitsubishi Tanabe collaboration for valbenazine in Japan and other select Asian markets. Operating expenses rose to $114.0 million from $64.4 million, driven by research and development expense of $81.5 million (up from $46.4 million) and general and administrative expense of $32.5 million (up from $18.0 million). The company had no approved products and an accumulated deficit of $915.2 million at December 31, 2015. The company's two lead late-stage programs are elagolix, a GnRH antagonist partnered with AbbVie for endometriosis and uterine fibroids, and valbenazine (NBI-98854), a VMAT2 inhibitor in Phase III for tardive dyskinesia and Phase II for Tourette syndrome. The filing states that AbbVie is targeting a 2017 New Drug Application filing for elagolix in endometriosis, and that the company expects to file a New Drug Application for valbenazine in tardive dyskinesia in 2016. The company also expects to increase general and administrative expense significantly in 2016 to prepare for valbenazine's commercialization, and expects a net loss in 2016. At December 31, 2015, cash, cash equivalents and investments totaled $461.7 million, up from $231.3 million a year earlier, following a $270.7 million net equity offering in February 2015. Management states that existing capital resources, investment income and future strategic alliance payments will be sufficient for at least the next 12 months. Mount Sinai filed a complaint in December 2015 alleging that the company breached its GnRH license by entering the AbbVie collaboration; the company intends to defend the claims vigorously.

    Feb 11, 2016
  13. 2014

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2014

    Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported in its 10-K for fiscal 2014 that it has not generated any revenue from product sales and remains a clinical-stage company. Its two lead late-stage programs are elagolix, a GnRH antagonist for endometriosis and uterine fibroids partnered with AbbVie Inc., and a wholly owned VMAT2 inhibitor (NBI-98854) for tardive dyskinesia, which is in Phase III. The company also advanced a CRF1 antagonist (NBI-77860) for classic congenital adrenal hyperplasia into clinical development in 2014. Total revenues were zero in 2014, compared with $2.9 million in 2013 and $53.1 million in 2012, while operating expenses rose to $64.4 million from $52.6 million, driven by higher research and development expense of $46.4 million and general and administrative expense of $18.0 million. The net loss widened to $60.5 million, or $0.81 per share, from $46.1 million, or $0.69 per share. The balance sheet strengthened over the year. Cash, cash equivalents and investments totaled $231.3 million at December 31, 2014, up from $145.7 million, after a February 2014 public offering of 8.0 million shares that netted approximately $133.2 million. The company reports no outstanding debt and an accumulated deficit of $826.3 million. Management states that existing capital resources, investment income and future alliance payments will be sufficient for at least the next 12 months, and it expects a net loss and higher expenses in 2015 as VMAT2 Phase III development and the CAH program advance and commercial preparation for tardive dyskinesia begins. Key pipeline milestones cited in the filing include AbbVie's Violet PETAL Phase III elagolix results (announced January 8, 2015, with both doses meeting co-primary endpoints at months three and six), top-line Kinect 3 data for NBI-98854 expected in the second half of 2015, and the FDA's breakthrough therapy designation for NBI-98854 in tardive dyskinesia granted in October 2014. The company had 94 full-time employees at December 31, 2014 and is not a party to any material legal proceedings.

    Feb 9, 2015
  14. 2013

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2013

    Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported a net loss of $46.1 million, or $0.69 per share, for 2013, compared with net income of $5.0 million in 2012 and $37.6 million in 2011. Total revenues fell to $2.9 million in 2013 from $53.1 million in 2012 and $77.4 million in 2011, as collaboration revenue from AbbVie and Boehringer Ingelheim tapered off after their collaborative development and research periods ended in 2012. The company stated it does not expect to recognize any milestone revenue in 2014 and expects revenue to decline further, with a net loss again in 2014. Research and development expense rose to $39.2 million in 2013 from $37.2 million in 2012, driven mainly by external development spending on the VMAT2 program. The company's lead programs are elagolix, a GnRH antagonist in Phase III development for endometriosis and Phase II for uterine fibroids, partnered with AbbVie, and a wholly owned VMAT2 inhibitor (NBI-98854) in Phase II for tardive dyskinesia. Under the AbbVie agreement, the company received an $75 million upfront payment and is eligible for up to $480 million in development and regulatory payments and up to $50 million in commercial payments. At December 31, 2013, cash, cash equivalents and investments totaled $145.7 million, and the company had no outstanding debt. The company stated that existing capital resources, investment income and future alliance payments are expected to be sufficient for at least the next 12 months. The accumulated deficit was $765.8 million at year-end. The filing also describes the Kinect and Kinect 2 Phase IIb trials of NBI-98854, where the 2014 end-of-Phase II meeting request is expected to be filed in the first half of 2014. The company had approximately 81 full-time employees at December 31, 2013 and reported no material legal proceedings.

    Feb 11, 2014
  15. 2012

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2012

    Neurocrine Biosciences, Inc. (NBIX) reported total revenues of $53.1 million for 2012, down from $77.4 million in 2011, and net income of $5.0 million, or $0.08 per diluted share, compared with $37.6 million in 2011. The decline reflects the absence of $30.0 million in 2011 AbbVie milestone revenue and lower collaboration revenue as the AbbVie and Boehringer Ingelheim collaborative periods were completed in 2012. Management expects revenue to decrease significantly in 2013, does not expect milestone revenue in 2013, and expects a net loss in 2013 as VMAT2 development spending rises. The company's lead clinical program is elagolix, an oral GnRH antagonist for endometriosis and uterine fibroids, which is partnered with AbbVie. AbbVie made a $75 million upfront payment and is responsible for development and commercialization costs; the endometriosis Phase III program began in the second quarter of 2012 with an NDA filing expected in 2016. The company's own pipeline centers on NBI-98854, a VMAT2 inhibitor for tardive dyskinesia, with Kinect (topline expected Q2 2013) and Kinect 2 (topline expected mid-2013) Phase IIb studies underway. Cash, cash equivalents and investments were $173.5 million at year-end 2012, the company had an accumulated deficit of $719.7 million, and it had no outstanding debt. The company reported no material legal proceedings and said its existing resources, together with investment income and future strategic alliance payments, would fund planned operations for at least the next 12 months. Investors should note that the company has not yet obtained approval for any product, has not generated product sales, and has stated it does not expect to remain profitable or cash flow positive for the foreseeable future.

    Feb 8, 2013
  16. 2011

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2011

    Neurocrine Biosciences, Inc. (NBIX) reported net income of $37.6 million, or $0.67 per diluted share, for 2011, compared with a net loss of $8.0 million in 2010. Total revenues were $77.4 million in 2011, up from $33.5 million in 2010, driven primarily by $30.0 million in milestone revenue under the Abbott collaboration and $34.0 million of amortization of up-front license fees. The company stated it did not generate positive cash flow from operations in 2011 (net cash used in operating activities was $0.7 million) and expects a net loss in 2012 because it does not anticipate milestone revenue that year. It also expects revenue to decrease significantly in 2012. The company is a clinical-stage developer with no approved products and an accumulated deficit of $724.7 million at December 31, 2011. Its lead program, elagolix for endometriosis, is partnered with Abbott International Luxembourg S.à r.l.; Abbott made a $75 million upfront payment and may pay up to $480 million in development and regulatory milestones plus up to $50 million in commercial milestones. The company expects elagolix to enter Phase III endometriosis trials in the first half of 2012, subject to finalizing a Special Protocol Assessment. Its VMAT2 inhibitor NBI-98854 is in Phase II for tardive dyskinesia, and the indiplon insomnia NDA remains approvable, with a 2007 FDA letter setting new requirements and the company having ceased U.S. development activities. Liquidity stood at $129.1 million in cash, cash equivalents and investments at December 31, 2011. In January 2012 the company completed a public offering of 10.9 million shares at $8.10 per share, with net proceeds of approximately $82.8 million. The company states its existing resources, together with investment income and future alliance payments, are sufficient for at least the next 12 months, and it has an effective shelf registration with approximately $37 million still available as of January 31, 2012.

    Feb 9, 2012
  17. 2010

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2010

    Neurocrine Biosciences, Inc. (NBIX) reported a net loss of $8.0 million, or $0.15 per share, for 2010, sharply narrower than the $51.0 million net loss in 2009. Total revenues rose to $33.5 million from $3.0 million, driven by the June 2010 collaborations with Abbott International Luxembourg S.à r.l. and Boehringer Ingelheim International GmbH. Cash, cash equivalents and investments totaled $130.6 million at December 31, 2010, compared with $59.9 million a year earlier, and the company had an accumulated deficit of $762.3 million. The company says it expects to be profitable in 2011 mainly because of a full year of activity under those collaborations, but does not expect to be operating cash flow positive in 2011 or to remain profitable beyond 2011. The lead program is elagolix, an oral GnRH antagonist for endometriosis that is partnered with Abbott. Abbott paid a $75 million upfront payment and may pay up to approximately $530 million in milestones. The company and Abbott have scheduled an end-of-Phase II meeting with the FDA in March 2011, and the company expects elagolix to enter Phase III trials in 2011, subject to FDA agreement on the trial design. The FDA-requested modified daily pain scales were used in the 901 study, which showed improvement in the elagolix arms. The filing also notes that the CRF1 antagonist 561679 showed no benefit over placebo in a Phase II major depressive disorder trial, and that indiplon has received an approvable letter from the FDA with new requirements, after which clinical development in the United States ceased. Financing sources include a $125 million shelf registration declared effective in December 2010 and a Committed Equity Financing Facility with Kingsbridge Capital Limited for up to $75 million, under which no shares had been issued as of year-end. Operating risks are concentrated in the clinical trial outcomes, dependence on collaborators, the need for future funding, and reliance on third-party manufacturers.

    Feb 10, 2011
  18. 2009

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2009

    Neurocrine Biosciences, Inc. (NBIX) reported a net loss of $51.0 million, or $1.30 per share, for 2009, compared with $88.6 million, or $2.30 per share, in 2008. Total revenues were $2.95 million in 2009, down from $3.98 million in 2008, and the company stated it has not generated any revenue from product sales. The company had an accumulated deficit of $754.3 million at December 31, 2009, and stockholders' equity of $3.95 million. Cash, cash equivalents and investments totaled $59.9 million at year-end 2009, down from $101.5 million at year-end 2008. Management believes existing resources, investment income and future alliance payments will fund operations for at least the next 12 months, and states it does not expect to be profitable in 2010 or the foreseeable future. The company's lead program is elagolix, an oral GnRH antagonist for endometriosis, which is in Phase II. Management plans an end-of-Phase II meeting with the FDA in mid-2010 and states that elagolix Phase III trials will not begin until the program is partnered. Other pipeline programs include a CRF1 antagonist being advanced by GlaxoSmithKline, urocortin 2 for heart failure, and a VMAT2 inhibitor in Phase I. Indiplon, the insomnia candidate, received a 2007 FDA approvable letter with new requirements, and the company ceased U.S. indiplon development activities and is evaluating alternatives. Funding relies on a $140 million shelf registration, a Committed Equity Financing Facility with Kingsbridge Capital of up to $75 million, and a December 2009 sale of about 4.8 million shares for $10.0 million gross. Headcount was approximately 65 employees as of January 31, 2010, following a May 2009 restructuring. The filing also notes $20.4 million (par) of auction rate securities that remain illiquid.

    Feb 8, 2010
  19. 2008

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2008

    Neurocrine Biosciences, Inc. (NBIX) reports a net loss of $88.6 million for 2008, compared with $207.3 million in 2007 and $107.2 million in 2006. The 2007 loss included a $94.0 million non-cash impairment of a prepaid royalty on indiplon. Total revenues were $4.0 million in 2008 versus $1.2 million in 2007, and the company states it has not generated revenue from product sales and does not expect to be profitable in 2009 or the foreseeable future. The accumulated deficit reached $703.3 million at December 31, 2008. Cash, cash equivalents and short-term investments were $80.5 million at year-end, with long-term investments of $21.1 million including $18.7 million of auction rate securities at carrying value, and the company states that existing resources should be sufficient for at least the next 12 months. The company's pipeline centers on elagolix, an oral GnRH antagonist in Phase II for endometriosis, with Phase III trials expected to begin in early 2010 if the end-of-Phase II meeting with the FDA proceeds as planned. Its CRF programs are partnered with GlaxoSmithKline, and indiplon for insomnia has an FDA approvable letter for 5mg and 10mg capsules that carries new requirements, after which the company ceased U.S. indiplon clinical development activities. The company also reported restructuring activities, including a $15.7 million cease-use expense tied to the front building of its San Diego headquarters, and it expects research and development and SG&A expenses to decrease in 2009. The filing also discloses that the company had approximately 125 employees as of January 31, 2009, and that securities class action and derivative litigation related to indiplon were dismissed in late 2008. Investors should weigh the company's continued losses, dependence on collaborators, and regulatory uncertainty around indiplon against its late-stage elagolix program and existing collaboration income.

    Feb 4, 2009
  20. 2007

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2007

    Neurocrine Biosciences, Inc. (NBIX) reported a net loss of $207.3 million for 2007, or $5.45 per share, compared with $107.2 million in 2006. Total revenues fell to $1.2 million from $39.2 million, reflecting the absence of Pfizer collaboration revenue recognized in 2006. The loss includes a $94.0 million non-cash impairment of a prepaid royalty on indiplon, recorded after the FDA issued a second approvable letter in December 2007. The company has no marketed products, reports an accumulated deficit of $614.7 million, and states it does not expect to be profitable in 2008. The company's regulatory outlook for its lead insomnia candidate, indiplon, is uncertain. The FDA's December 12, 2007 approvable letter for the 5mg and 10mg capsules set new requirements, including an elderly clinical trial, a safety study versus a marketed product, and a preclinical third-trimester pregnancy study. The company ceased indiplon clinical development and pre-commercialization activities in the U.S., and the 15mg tablets remain not approvable. Indiplon rights in Japan were licensed to Dainippon Sumitomo Pharma for a $20.0 million upfront fee, with up to $115.0 million in additional milestones possible. The pipeline centers on a GnRH antagonist for endometriosis, with a Phase IIb study expected to report top-line results in mid-2008, and CRF1 antagonist work partnered with GlaxoSmithKline. The company cut costs through a December 2007 restructuring of about 125 employees, expected to reduce annual expenses by approximately $18.0 million, and a sale-leaseback of its San Diego facility for $109.0 million. Cash, cash equivalents and short-term investments totaled $179.4 million at year-end, and management believes existing resources are sufficient for at least the next 12 months. Securities class action and derivative lawsuits related to indiplon are pending.

    Feb 11, 2008
  21. 2006

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2006

    Neurocrine Biosciences, Inc. is a Delaware corporation that discovers and intends to commercialize drugs for neurological and endocrine-related diseases. Its lead product candidate, indiplon for insomnia, received two complete responses from the FDA on May 15, 2006: indiplon 5 mg and 10 mg capsules were deemed approvable, while the 15 mg tablets were deemed not approvable. The company plans to resubmit the capsule NDA by the end of the second quarter of 2007, and is evaluating a sleep maintenance claim for both formulations. Following the termination of its Pfizer collaboration effective December 19, 2006, Neurocrine reacquired all worldwide rights to indiplon and is responsible for its future costs; it will seek a new partner at an appropriate time. Financially, total revenues fell to $39.2 million in 2006 from $123.9 million in 2005, mainly because 2005 included $70.0 million in Pfizer milestones. The net loss widened to $107.2 million, or $2.84 per share, from $22.2 million in 2005. The accumulated deficit reached $407.4 million, and cash, cash equivalents and short-term investments totaled $182.6 million at year-end, down from $273.1 million. The company expects revenues and SG&A to decrease significantly in 2007, expects to use about $80.0 million of cash in 2007, and expects to end the year with at least $100.0 million. It states that it does not expect to be profitable in 2007 and that its existing resources should suffice for at least the next 12 months. The company also restructured in 2006: it terminated its 200-person sales force in July 2006 and cut about 100 San Diego R&D and G&A positions in August 2006, recording a charge of about $9.5 million. Pipeline programs include a GnRH antagonist for endometriosis in Phase II/IIb, a CRF R1 antagonist partnered with GlaxoSmithKline (now in Phase II for social anxiety disorder and irritable bowel syndrome), urocortin 2 for congestive heart failure in Phase II, and a selective norepinephrine reuptake inhibitor for neuropathic pain in Phase I.

    Feb 9, 2007
  22. 2005

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2005

    Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported a net loss of $22.2 million, or $0.60 per share, for 2005, compared with a net loss of $45.8 million, or $1.26 per share, in 2004. Total revenues rose to $123.9 million from $85.2 million, driven mainly by $70.0 million in milestones from Pfizer tied to FDA acceptance of the indiplon NDAs, along with a $22.0 million sales force allowance from Pfizer. Research and development expenses fell to $106.6 million from $115.1 million as the indiplon Phase III program wound down, while sales, general and administrative expenses rose to $42.3 million, reflecting the 200-person sales force. The company had an accumulated deficit of $300.1 million and cash, cash equivalents and short-term investments of $273.1 million at December 31, 2005. The central near-term catalyst is indiplon for insomnia. The FDA accepted NDAs for the capsule and tablet formulations, and the PDUFA dates were moved to May 15, 2006 for the capsule and June 27, 2006 for the tablet, with the FDA committing to an action on both by May 15, 2006. The company says it expects 2006 to be roughly break-even before indiplon royalty revenue and the adoption of SFAS 123R, but profitability depends on FDA approval and market acceptance. Pfizer, the collaboration partner, may terminate its agreement on 180 days' notice. The pipeline includes GnRH antagonists for endometriosis and benign prostatic hyperplasia, altered peptide ligands for multiple sclerosis and type 1 diabetes, CRF receptor antagonists with GlaxoSmithKline, and urocortin 2 for heart failure. The company states that its existing capital resources and collaboration payments will be sufficient for at least the next 12 months.

    Feb 7, 2006
  23. 2004

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2004

    Neurocrine Biosciences, Inc. reported a net loss of $45.8 million, or $1.26 per share, for 2004, compared with a net loss of $30.3 million, or $0.93 per share, in 2003. Total revenues were $85.2 million in 2004, down from $139.1 million in 2003, as sponsored development revenue fell from $96.7 million to $27.2 million with the winding down of the Phase III indiplon program. Milestones and license fees rose to $57.6 million, including $20.5 million in Pfizer milestones tied to Phase III studies. The accumulated deficit reached $278.0 million at year-end 2004. The company's lead product candidate is indiplon, a non-benzodiazepine GABA-A agonist for insomnia, partnered with Pfizer. Neurocrine submitted new drug applications for indiplon immediate release capsules in October 2004 and modified release tablets in November 2004. In December 2004 the FDA did not accept the IR NDA due to difficulties navigating the electronic filing, and the company withdrew the MR application. Neurocrine plans to refile the IR NDA at the end of the first quarter or beginning of the second quarter of 2005 and the MR NDA in the second quarter of 2005. Pfizer is to fund a 200-person sales force starting in 2005, and the filing states that the company expects indiplon to be commercially available by 2006. At December 31, 2004, cash, cash equivalents and short-term investments totaled $301.1 million, down from $453.2 million a year earlier, after a $50.0 million payment to Wyeth for the indiplon royalty stream and operating losses. Operating cash flow was negative $100.0 million in 2004. The company stated that existing capital resources, interest income and future alliance payments are expected to be sufficient for at least the next 12 months.

    Feb 16, 2005
  24. 2003

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2003

    Neurocrine Biosciences, Inc. (NBIX) reported a net loss of $30.3 million, or $0.93 per share, for 2003, compared with a net loss of $94.5 million, or $3.10 per share, in 2002. Total revenues rose to $139.1 million from $18.0 million, driven mainly by $90.9 million of sponsored development reimbursements and $38.0 million of amortized upfront fees under the Pfizer collaboration for indiplon, its lead insomnia candidate. Research and development expenses increased to $177.3 million, and the company stated it expects R&D expenses to decrease in 2004 as the indiplon Phase III program completes. The company expects to file a New Drug Application for indiplon in mid-2004 and anticipates its first product revenues in 2005, with a return to profitability expected that year. Year-end 2003 cash, cash equivalents and short-term investments totaled $453.2 million, up from $244.7 million a year earlier, reflecting the $100.0 million Pfizer upfront payment and $187.4 million of net proceeds from a September 2003 stock offering. The company also recorded a one-time gain of approximately $18.0 million on the sale of its former headquarters to Pfizer. Accumulated deficit stood at $232.2 million, and the company stated its existing capital resources are sufficient for at least the next 12 months. Subsequent to year-end, on February 26, 2004, the company agreed to acquire Wyeth's financial interest in indiplon for approximately $95 million ($50 million in cash and $45 million in common stock), reducing its royalty obligation to DOV on indiplon sales from six percent to three and one-half percent. The transaction was scheduled to close on March 15, 2004. The company also disclosed a pending arbitration filed by The Salk Institute over alleged unpaid milestone payments, which management believes will not have a material adverse effect.

    Mar 15, 2004
  25. 2002

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2002

    Neurocrine Biosciences, Inc. is a San Diego-based company developing drugs for neurologic and endocrine diseases. Its 2002 results show revenues of $18.0 million, down from $41.2 million in 2001, driven primarily by $21.0 million of milestones achieved in 2001 under the Taisho and GSK collaborations. Research and development expenses rose to $108.9 million from $74.3 million, and the net loss widened to $94.5 million, or $3.10 per share, from $36.9 million, or $1.42 per share. The accumulated deficit reached $201.9 million, and cash, cash equivalents and short-term investments totaled $244.7 million at December 31, 2002. The company's lead program is indiplon for insomnia, which is in Phase III trials. In December 2002, Neurocrine entered a collaboration with Pfizer on indiplon under which the company received an upfront payment of $100 million, expected in early 2003, and is eligible for up to $300 million in additional pre-commercialization milestones. Pfizer also committed to a secured short-term loan of up to $175 million, subject to U.S. launch and other conditions. The company plans to file a New Drug Application for indiplon in late December 2003 or early 2004. The pipeline spans seven clinical-stage programs and nine research programs, including altered peptide ligands for multiple sclerosis and Type 1 diabetes, a CRF R1 antagonist with GlaxoSmithKline, a GnRH antagonist, and the IL-4 fusion toxin NBI-3001 for cancer. The company states it has no product approved and expects losses to continue. Management believes existing resources, interest income and future alliance payments will fund operations for at least the next 12 months.

    Mar 4, 2003
  26. 2001

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2001

    Neurocrine Biosciences, Inc. reported a net loss of $36.9 million, or $1.42 per share, for the fiscal year ended December 31, 2001, compared with a net loss of $28.8 million, or $1.30 per share, in 2000. Total revenues rose to $41.2 million from $14.6 million, driven mainly by the Taisho and GSK collaborations, while research and development expense increased to $74.3 million from $40.2 million. The company stated it does not expect to be profitable in 2002 and had an accumulated deficit of $107.4 million at year-end. It has no approved products; all of its product candidates are in research or clinical development. The lead program is NBI-34060, a GABA-A agonist for insomnia in Phase III trials, with the first Phase III study begun in November 2001 and an planned program of approximately 3,300 additional subjects in eight large trials. Other clinical programs include NBI-34041, a CRF R1 antagonist in Phase I with GlaxoSmithKline, NBI-3001 (IL-4 fusion toxin) for malignant glioma and other cancers, and altered peptide ligands for multiple sclerosis and Type 1 diabetes. Cash, cash equivalents and short-term investments totaled $320.0 million at December 31, 2001, following a December 2001 public offering of 4.0 million shares that generated net proceeds of $175.6 million. The company states that existing resources, together with interest income and future alliance payments, will be sufficient for at least the next twelve months. Janssen notified the company in March 2002 that it had terminated its 1995 and 1999 agreements, returning exclusive rights to the first generation CRF R1 antagonist compounds to Neurocrine, and the company does not expect additional payments under those agreements. The company reported no material legal proceedings.

    Mar 26, 2002
  27. 2000

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2000

    Neurocrine Biosciences, Inc. reported a net loss of $28.8 million, or $1.30 per share, for the year ended December 31, 2000, compared with a net loss of $16.8 million, or $0.88 per share, in 1999. Total revenues were $14.6 million, down from $16.8 million in 1999, mainly because the Novartis collaboration ended in January 2000 and the sponsored research portion of the Eli Lilly collaboration ended in October 1999. Research and development expenses rose to $40.2 million from $29.2 million, and the company says it expects operating losses to increase as clinical development expands. The balance sheet strengthened over the year. Cash, cash equivalents and short-term investments totaled $164.7 million at year-end, up from $91.1 million, driven mainly by a December 2000 public offering of 3.2 million shares at $30 per share that produced net proceeds of $90.4 million. Stockholders' equity was $163.2 million, and the accumulated deficit reached $70.5 million. The company states that its existing capital resources, together with interest income and future alliance payments, will be sufficient for at least the next 12 months. The company's lead programs are NBI-34060, a GABA-A agonist for insomnia now in Phase II, and an IL-4 fusion toxin for malignant glioma. In 2001, it expects to spend about $35 million on clinical testing of the brain cancer and insomnia compounds. In December 2000, Taisho's collaboration on NBI-6024 for Type 1 diabetes was expanded to worldwide rights, with the collaboration valued at up to $100 million. The filing also notes that the 2000 net loss includes a $3.8 million cumulative effect from the adoption of SAB 101 on license fee revenue recognition.

    Mar 30, 2001
  28. 1999-A

    Neurocrine Biosciences Annual Report (Amendment), Year Ended Dec 31, 1999

    Neurocrine Biosciences, Inc. filed Amendment No. 1 to its Form 10-K for the fiscal year ended December 31, 1999. The company has not generated product revenues and expects none in the foreseeable future. Its 1999 revenues were $16.8 million, versus $16.0 million in 1998 and $26.1 million in 1997, and were driven by collaborations rather than product sales. Research and development expenses rose to $29.2 million and general and administrative expenses to $7.5 million, producing a net loss of $16.8 million, or $0.88 per share, compared with a net loss of $20.0 million, or $1.10 per share, in 1998. The company's cumulative deficit was $41.7 million at December 31, 1999. Liquidity improved during 1999. Cash, cash equivalents and short-term investments totaled $91.1 million at year-end, up from $62.7 million a year earlier, after a December 1999 private placement of 2.3 million shares at $18.00 per share that produced net proceeds of $39.3 million. Management believes existing capital resources, interest income and future collaboration payments will be sufficient for at least the next 12 months, but it expects operating losses over the next two to three years as clinical development grows. The company also states that it will need additional funding and may seek equity markets, strategic alliances or other financing. The filing highlights the Wyeth-Ayerst collaboration on excitatory amino acid transporters, which is valued at up to $81 million if a product is commercialized, and the Taisho option agreement for an altered peptide ligand for diabetes, which could be worth up to $45 million. It also notes that Novartis terminated its multiple sclerosis agreement, returning worldwide rights to compound MSP771. The company expects to spend about $20 million in 2000 on clinical testing of its insomnia and brain cancer compounds, and it notes that the Year 2000 remediation program cost an estimated $175,000 with no material adverse effects reported.

    Nov 30, 2000
  29. 1999

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 1999

    Neurocrine Biosciences, Inc. reported a net loss of $16.8 million, or $0.88 per share, for the fiscal year ended December 31, 1999, compared with a net loss of $20.0 million, or $1.10 per share, in 1998 and net income of $5.1 million, or $0.30 per share, in 1997. Total revenues were $16.8 million in 1999 versus $16.0 million in 1998, while research and development expenses rose to $29.2 million from $21.8 million and general and administrative expenses rose to $7.5 million from $6.6 million. The company has no approved products and states that all of its product candidates are at an early stage of development, with revenues expected to come from strategic alliances. The company's pipeline spans five clinical programs: a CRF receptor antagonist partnered with Janssen for anxiety/depression (Phase II), NBI-34060 for insomnia (Phase II, with a 228-subject transient insomnia study completed), the IL-4 Fusion Toxin NBI-3001 for glioblastoma (Phase I/II, with FDA Fast Track Designation granted in October 1999), an altered peptide ligand for multiple sclerosis (Phase II, reacquired from Novartis on January 7, 2000), and an altered peptide ligand for Type I diabetes (Phase I). The company closed a private placement of 2.3 million shares at $18.00 per share in December 1999, with net proceeds of $39.3 million. Cash, cash equivalents and short-term investments totaled $91.1 million at year-end, and management states that existing resources are sufficient through 2003, though it expects similar operating losses over the next two to three years. Key risks highlighted in the filing include dependence on strategic partners, reliance on third-party contract manufacturers, intense competition from better-capitalized companies, uncertainty in clinical and regulatory outcomes, and the possibility of additional dilutive financing. The filing also notes that the Taisho agreement for the diabetes APL is an option that Taisho may or may not exercise, and that the company sold its interest in Neuroscience Pharma Inc. in December 1999.

    Mar 30, 2000
  30. 1998

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 1998

    Neurocrine Biosciences, Inc. filed this Form 10-K for the fiscal year ended December 31, 1998, describing itself as a neuroscience company focused on discovering and developing therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases. Total revenues were $16.0 million in 1998, down from $26.1 million in 1997, while research and development expenses rose to $21.8 million and a $4.9 million write-off of acquired in-process R&D related to the Northwest NeuroLogic acquisition and licenses was taken. The company reported a net loss of $20.0 million, or $1.10 per share, compared with net income of $5.1 million in 1997, and its accumulated deficit grew to $24.9 million. The filing states the company has no product revenues and expects to rely on strategic alliances with Janssen, Novartis, Eli Lilly and Wyeth-Ayerst, and that existing capital resources together with alliance payments will be sufficient at least through 2000. The company's pipeline includes five clinical programs: a CRF receptor antagonist in Phase II with Janssen for anxiety and depression, an altered peptide ligand for multiple sclerosis in Phase II with Novartis, an IL-4 Fusion Toxin in Phase I/II for glioblastoma, a GABA receptor subtype agonist (NBI-34060) for insomnia, and an altered peptide ligand for Type I diabetes in Phase I. Cash, cash equivalents and short-term investments totaled $62.7 million at year-end 1998, down from $75.1 million in 1997. The filing also reports that the DHEA neurosteroid program was discontinued in March 1999 after a Phase II/III trial failed to show a difference from placebo, and that a March 2, 1999 collaboration with Wyeth-Ayerst on excitatory amino acid transporters is valued at up to $78 million. The filing discloses material risks, including dependence on corporate partners that can terminate their agreements, a third-party patent application that could affect Janssen's lead CRF compound, and reliance on contract manufacturers. The company had 149 employees as of December 31, 1998.

    Mar 31, 1999
  31. 1997

    Neurocrine Biosciences Annual Report, Year Ended Dec 31, 1997

    Neurocrine Biosciences, Inc. (NBIX) reported its 10-K for fiscal year ended December 31, 1997. The company describes itself as a neuroimmunology company developing therapeutics for central nervous and immune system diseases, with all product candidates in research or early development and no regulatory approval requested or received for any product. Its lead programs include CRF receptor antagonists (Janssen, Phase I for anxiety and depression), CRF-binding protein antagonists (Lilly, for obesity and Alzheimer's), altered peptide ligands for multiple sclerosis (Novartis, Phase II), and DHEA for Alzheimer's (Phase II/III in Canada and other countries). Financially, total revenues rose to $26.1 million in 1997 from $19.2 million in 1996, driven by sponsored research, milestones and other revenues, while research and development expense increased to $19.9 million from $12.6 million. Net income declined to $5.1 million, or $0.28 per diluted share, from $5.9 million, or $0.36 per diluted share, in 1996. Cash, cash equivalents and short-term investments totaled $75.1 million at year-end, and management states that existing resources, together with interest income and future alliance payments, should fund operations at least through 2000. The company has no product revenues and relies on its three collaborations for funding. The filing also discloses a February 27, 1998 letter of intent to acquire Northwest NeuroLogic, Inc. in a 100% stock transaction valued at approximately $4.0 million.

    Apr 10, 1998